CONMED Corporation Lowers Organic Growth Outlook and Provides 2026 EPS Guidance
CONMED Corporation (CNMD) reported third-quarter net revenue of $335.6 million, noting mixed sales results. While overall figures were impacted by the exit from certain gastrointestinal (GI) products, management highlighted stronger underlying organic growth when excluding those discontinued lines. The company has tightened its organic growth outlook to a range of 5% to 5.5%. Looking further ahead, CONMED provided long-term guidance forecasting an adjusted earnings per share (EPS) between $4.54 and $4.61 for the fiscal year 2026.
Tickers: $CNMD
Topics: earnings report organic growth revenue growth
Read the full article at Seeking Alpha
Part of the story Hubbell Projects 2026 EPS Growth Amid Rising Electrical Solutions Organic Outlook (6 articles)